The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

A briefing document from the Food and Drug Administration (FDA) says that enrollment for all clinical studies of vaccines for ...

Ahead of an advisory committee meeting later this week, the FDA revealed that all studies for RSV vaccines in young children ...

Along with holiday arrangements, changing seasons signal the need for another type of preparation: vaccination.

Analysts issued an Underperform rating for shares while reluanching coverage of large-cap U.S. pharma and biotech names.

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/91.DyCR3BqR.js ...

MinterEllison has advised Moderna in relation to its new mRNA manufacturing facility – a facility described by the firm as ...

challenging to see how Moderna generates >$2bn per annum from a COVID shot. There is also debate around what age groups ought to receive an RSV vaccine, and this could be an area where the HHS ...

Although the FDA has expanded approvals for two respiratory syncytial virus (RSV) vaccines to include high-risk young and ...

The Southern Hemisphere’s only mRNA manufacturing facility has opened in Victoria to ensure world-class mRNA vaccines and ...